Blueprint Medicines Corp (BPMC) 28.26 $BPMC
Systemic Mastocytosis - Pipeline Review, H1 2015
M2 - Wed Aug 05, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/958kfl/systemic) has announced the addition of the "Systemic Mastocytosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Mastocytosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Mastocytosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AB Science - Blueprint Medicines - Bristol-Myers Squibb - Novartis - Patara Pharma - Pharmacyclics - Stemline Therapeutics For more information visit http://www.researchandmarkets.com/research/958kfl/systemic
BPMC: 28.26 (-0.17), BMY: 65.06 (+0.22), STML: 10.35 (-0.02), NVS: 103.25 (-0.32)
Blueprint Medicines to Present at 2015 Wedbush PacGrow Healthcare Conference
PR Newswire - Tue Aug 04, 7:00AM CDT
Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced that Jeffrey Albers, chief executive officer, will present a company overview at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 1:20 p.m. EDT.
BPMC: 28.26 (-0.17)
Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for Two Drug Candidates
PR Newswire - Mon Jul 13, 7:05AM CDT
Blueprint Medicines (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST). Blueprint Medicines is also on track to file an IND for BLU-285 in systemic mastocytosis.
BPMC: 28.26 (-0.17)
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
M2 - Thu Jul 09, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdk8kj/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Advenchen Laboratories, LLC - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Blueprint Medicines - Boston Biomedical, Inc. - Chipscreen Biosciences Ltd - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Jiangsu Hengrui Medicine Co., Ltd. - Natco Pharma Limited - Nerviano Medical Sciences S.r.l. - Novartis AG - Otsuka Holdings Co., Ltd. - Plexxikon Inc. - Synta Pharmaceuticals Corp. - Takeda Pharmaceutical Company Limited - Threshold Pharmaceuticals, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alpelisib - apatinib - BBI-503 - binimetinib - BLU-285 - buparlisib hydrochloride - crenolanib besylate - CS-2164 - DCC-2618 - evofosfamide - ganetespib - LOP-628 - masitinib - motesanib diphosphate - nilotinib - NMSP-088 - NRCAN-019 - onalespib - OPB-51602 - pazopanib hydrochloride - PLX-3397 - ponatinib hydrochloride - quizartinib dihydrochloride - SF-1126 - SHR-1020 - Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - vemurafenib For more information visit http://www.researchandmarkets.com/research/kd...intestinal
BPMC: 28.26 (-0.17), GSK: 44.17 (+0.72), SNTA: 2.06 (-0.03), ARRY: 6.10 (+0.29), NVS: 103.25 (-0.32)
Blueprint Medicines Added to Russell 2000®, 3000® and Global Indexes
PR Newswire - Mon Jun 29, 7:00AM CDT
Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Global Indexes as part of Russell Investments' annual reconstitution that took place after market close on June 26, 2015.
BPMC: 28.26 (-0.17)
Blueprint Medicines (BPMC) Falls: Stock Goes Down 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 22, 7:38AM CDT
Blueprint Medicines (BPMC) fell nearly 8% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up over 14% in the past one month.
BPMC: 28.26 (-0.17)
Blueprint Medicines reports Q1 results
Seeking Alpha - at Seeking Alpha - Fri Jun 12, 6:15AM CDT
BPMC: 28.26 (-0.17)
Blueprint Medicines reports FQ1 results
Seeking Alpha - at Seeking Alpha - Thu Jun 11, 3:25PM CDT
BPMC: 28.26 (-0.17)
Blueprint Medicines Reports First Quarter 2015 Financial Results
PR Newswire - Thu Jun 11, 3:05PM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2015.
BPMC: 28.26 (-0.17)
Blueprint Medicines to Present at Upcoming Investor Conferences in June
PR Newswire - Fri Jun 05, 7:30AM CDT
Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced its participation in the following upcoming investor conferences:
BPMC: 28.26 (-0.17)
Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Tue May 26, 12:43PM CDT
BPMC: 28.26 (-0.17), TRVN: 6.46 (-0.07), ESPR: 60.28 (-1.64), QURE: 26.10 (-0.19), STEM: 0.42 (unch), APDN: 2.61 (+0.09), SMED: 6.53 (-0.01), HZNP: 35.06 (+0.06), ICPT: 260.13 (+0.04), ALKS: 72.17 (+1.92)
Blueprint Medicines Publishes Strategy for Advancing Kinase Drug Discovery
PR Newswire - Mon May 11, 6:30AM CDT
Blueprint Medicines (NASDAQ: BPMC) today announced that the Journal of Clinical Investigation (JCI) published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets. "Targeting cancer with kinase inhibitors," authored by Blueprint Medicines' scientists, was published in the May 2015 issue of JCI, a leading journal focused on science and clinical research to advance medicine.
BPMC: 28.26 (-0.17)
InsiderInsights.com Daily Round Up 5/7/15: SGEN, GFF, OPK, SAM
InsiderInsights - at Seeking Alpha - Sun May 10, 5:00AM CDT
BPMC: 28.26 (-0.17), MRLN: 15.77 (+0.16), FRPT: 17.37 (+0.32), GFF: 17.51 (+0.18), SAM: 233.22 (-1.56), MOH: 77.24 (+1.84), CARB: 11.77 (-0.01), SGEN: 46.83 (-0.01), OPK: 16.11 (+0.01), PZZA: 71.45 (-4.16), CBNJ: 10.95 (+0.23), CRUS: 29.98 (+0.57), DYN: 24.23 (-0.22), JGW: 8.39 (-0.42), MAC: 79.81 (+1.01), CMCSA: 59.81 (-2.93), FTNT: 48.83 (+1.15), AN: 61.80 (+0.68)
Blueprint Medicines Announces Closing of Initial Public Offering
PR Newswire - Tue May 05, 3:14PM CDT
Blueprint Medicines (NASDAQ: BPMC) today announced the closing of its initial public offering of 9,367,708 shares of common stock at a public offering price of $18.00 per share, including shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the initial public offering to Blueprint Medicines were approximately $168.6 million, before underwriting discounts and estimated offering expenses.
BPMC: 28.26 (-0.17)
U.S. IPO Weekly Recap: 4 IPOs Offer Dividends And Drugs
Renaissance Capital IPO Research - Seeking Alpha - Sat May 02, 12:45PM CDT
Yield IPOs yielded disappointing returns while biotech performance was anemic. 13 companies were added to the IPO calendar - including 7 in the health care sector - making this an inopportune week for a drop in the NASDAQ Composite. 49 companies...
BPMC: 28.26 (-0.17), EVA: 15.82 (-0.05), BSM: 13.89 (-0.54), VKTX: 6.10 (+0.20)
IPO Preview: Blueprint Medicines
IPOdesktop - Seeking Alpha - Thu Apr 30, 8:51AM CDT
Based in Cambridge, MA, Blueprint Medicines (Pending: BPMC ) scheduled a $115 million IPO on Nasdaq with a market capitalization of $398 million at a price range midpoint of $16 for Thursday, April 30, 2015. The full IPO calendar is available at ...
BPMC: 28.26 (-0.17)
Blueprint Medicines Announces Pricing of Initial Public Offering
PR Newswire - Wed Apr 29, 5:56PM CDT
Blueprint Medicines today announced the pricing of its initial public offering of 8,145,834 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines granted the underwriters a 30-day option to purchase up to an additional 1,221,874 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on April 30, 2015 under the ticker symbol "BPMC."
BPMC: 28.26 (-0.17)
Blueprint Medicines - High Valuations On A Preclinical Pipeline
APBK Capital - at Seeking Alpha - Tue Apr 28, 10:05AM CDT
BPMC: 28.26 (-0.17)
Blueprint Medicines IPO: Early For Stamp Of Approval, But Goldman Could Power It Up
Don Dion - at Seeking Alpha - Tue Apr 28, 3:30AM CDT
BPMC: 28.26 (-0.17), ALXN: 197.94 (+0.79)
Week Ahead: 6 IPOs Planned For The Week Of April 27
Renaissance Capital IPO Research - at Seeking Alpha - Mon Apr 27, 5:53AM CDT
Up to six companies could price their IPOs this week . All are either LPs or healthcare companies (including three biotechs). Two LPs on deck, one offering power-generating wood pellets Enviva Partners LP (Pending: EVA ) is backed by...
BPMC: 28.26 (-0.17), EVA: 15.82 (-0.05), CLCD: 7.15 (-0.41), BSM: 13.89 (-0.54), VKTX: 6.10 (+0.20), OPGN: 3.22 (+0.07)
Systemic Mastocytosis - Pipeline Review, H1 2015
M2 - Wed Aug 05, 5:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/958kfl/systemic) has announced the addition of the "Systemic Mastocytosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Systemic Mastocytosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Systemic Mastocytosis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AB Science - Blueprint Medicines - Bristol-Myers Squibb - Novartis - Patara Pharma - Pharmacyclics - Stemline Therapeutics For more information visit http://www.researchandmarkets.com/research/958kfl/systemic
BPMC: 28.26 (-0.17), BMY: 65.06 (+0.22), STML: 10.35 (-0.02), NVS: 103.25 (-0.32)
Blueprint Medicines to Present at 2015 Wedbush PacGrow Healthcare Conference
PR Newswire - Tue Aug 04, 7:00AM CDT
Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced that Jeffrey Albers, chief executive officer, will present a company overview at the 2015 Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at 1:20 p.m. EDT.
BPMC: 28.26 (-0.17)
Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for Two Drug Candidates
PR Newswire - Mon Jul 13, 7:05AM CDT
Blueprint Medicines (NASDAQ: BPMC) today announced that the U.S. Food and Drug Administration (FDA) accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST). Blueprint Medicines is also on track to file an IND for BLU-285 in systemic mastocytosis.
BPMC: 28.26 (-0.17)
Gastrointestinal Stromal Tumor (GIST) Therapeutics Pipeline Review, H1 2015 - 21 Companies & 28 Drug Profiles
M2 - Thu Jul 09, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdk8kj/gastrointestinal) has announced the addition of the "Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Gastrointestinal Stromal Tumor (GIST), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastrointestinal Stromal Tumor (GIST) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Advenchen Laboratories, LLC - Ariad Pharmaceuticals, Inc. - Array BioPharma Inc. - Astex Pharmaceuticals, Inc. - Blueprint Medicines - Boston Biomedical, Inc. - Chipscreen Biosciences Ltd - Daiichi Sankyo Company, Limited - Deciphera Pharmaceuticals, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Jiangsu Hengrui Medicine Co., Ltd. - Natco Pharma Limited - Nerviano Medical Sciences S.r.l. - Novartis AG - Otsuka Holdings Co., Ltd. - Plexxikon Inc. - Synta Pharmaceuticals Corp. - Takeda Pharmaceutical Company Limited - Threshold Pharmaceuticals, Inc. Drug Profiles - (dabrafenib mesylate trametinib dimethyl sulfoxide) - alpelisib - apatinib - BBI-503 - binimetinib - BLU-285 - buparlisib hydrochloride - crenolanib besylate - CS-2164 - DCC-2618 - evofosfamide - ganetespib - LOP-628 - masitinib - motesanib diphosphate - nilotinib - NMSP-088 - NRCAN-019 - onalespib - OPB-51602 - pazopanib hydrochloride - PLX-3397 - ponatinib hydrochloride - quizartinib dihydrochloride - SF-1126 - SHR-1020 - Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - vemurafenib For more information visit http://www.researchandmarkets.com/research/kd...intestinal
BPMC: 28.26 (-0.17), GSK: 44.17 (+0.72), SNTA: 2.06 (-0.03), ARRY: 6.10 (+0.29), NVS: 103.25 (-0.32)
Blueprint Medicines Added to Russell 2000®, 3000® and Global Indexes
PR Newswire - Mon Jun 29, 7:00AM CDT
Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced that it has been added to the Russell 2000®, Russell 3000®, and Russell Global Indexes as part of Russell Investments' annual reconstitution that took place after market close on June 26, 2015.
BPMC: 28.26 (-0.17)
Blueprint Medicines (BPMC) Falls: Stock Goes Down 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 22, 7:38AM CDT
Blueprint Medicines (BPMC) fell nearly 8% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up over 14% in the past one month.
BPMC: 28.26 (-0.17)
Blueprint Medicines reports Q1 results
Seeking Alpha - at Seeking Alpha - Fri Jun 12, 6:15AM CDT
BPMC: 28.26 (-0.17)
Blueprint Medicines reports FQ1 results
Seeking Alpha - at Seeking Alpha - Thu Jun 11, 3:25PM CDT
BPMC: 28.26 (-0.17)
Blueprint Medicines Reports First Quarter 2015 Financial Results
PR Newswire - Thu Jun 11, 3:05PM CDT
Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2015.
BPMC: 28.26 (-0.17)
Blueprint Medicines to Present at Upcoming Investor Conferences in June
PR Newswire - Fri Jun 05, 7:30AM CDT
Blueprint Medicines (NASDAQ: BPMC), a leader in discovering and developing highly selective kinase drugs for genomically defined diseases, today announced its participation in the following upcoming investor conferences:
BPMC: 28.26 (-0.17)
Healthcare ratings roundup - new coverage
Seeking Alpha - at Seeking Alpha - Tue May 26, 12:43PM CDT
BPMC: 28.26 (-0.17), TRVN: 6.46 (-0.07), ESPR: 60.28 (-1.64), QURE: 26.10 (-0.19), STEM: 0.42 (unch), APDN: 2.61 (+0.09), SMED: 6.53 (-0.01), HZNP: 35.06 (+0.06), ICPT: 260.13 (+0.04), ALKS: 72.17 (+1.92)
Blueprint Medicines Publishes Strategy for Advancing Kinase Drug Discovery
PR Newswire - Mon May 11, 6:30AM CDT
Blueprint Medicines (NASDAQ: BPMC) today announced that the Journal of Clinical Investigation (JCI) published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets. "Targeting cancer with kinase inhibitors," authored by Blueprint Medicines' scientists, was published in the May 2015 issue of JCI, a leading journal focused on science and clinical research to advance medicine.
BPMC: 28.26 (-0.17)
InsiderInsights.com Daily Round Up 5/7/15: SGEN, GFF, OPK, SAM
InsiderInsights - at Seeking Alpha - Sun May 10, 5:00AM CDT
BPMC: 28.26 (-0.17), MRLN: 15.77 (+0.16), FRPT: 17.37 (+0.32), GFF: 17.51 (+0.18), SAM: 233.22 (-1.56), MOH: 77.24 (+1.84), CARB: 11.77 (-0.01), SGEN: 46.83 (-0.01), OPK: 16.11 (+0.01), PZZA: 71.45 (-4.16), CBNJ: 10.95 (+0.23), CRUS: 29.98 (+0.57), DYN: 24.23 (-0.22), JGW: 8.39 (-0.42), MAC: 79.81 (+1.01), CMCSA: 59.81 (-2.93), FTNT: 48.83 (+1.15), AN: 61.80 (+0.68)
Blueprint Medicines Announces Closing of Initial Public Offering
PR Newswire - Tue May 05, 3:14PM CDT
Blueprint Medicines (NASDAQ: BPMC) today announced the closing of its initial public offering of 9,367,708 shares of common stock at a public offering price of $18.00 per share, including shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the initial public offering to Blueprint Medicines were approximately $168.6 million, before underwriting discounts and estimated offering expenses.
BPMC: 28.26 (-0.17)
U.S. IPO Weekly Recap: 4 IPOs Offer Dividends And Drugs
Renaissance Capital IPO Research - Seeking Alpha - Sat May 02, 12:45PM CDT
Yield IPOs yielded disappointing returns while biotech performance was anemic. 13 companies were added to the IPO calendar - including 7 in the health care sector - making this an inopportune week for a drop in the NASDAQ Composite. 49 companies...
BPMC: 28.26 (-0.17), EVA: 15.82 (-0.05), BSM: 13.89 (-0.54), VKTX: 6.10 (+0.20)
IPO Preview: Blueprint Medicines
IPOdesktop - Seeking Alpha - Thu Apr 30, 8:51AM CDT
Based in Cambridge, MA, Blueprint Medicines (Pending: BPMC ) scheduled a $115 million IPO on Nasdaq with a market capitalization of $398 million at a price range midpoint of $16 for Thursday, April 30, 2015. The full IPO calendar is available at ...
BPMC: 28.26 (-0.17)
Blueprint Medicines Announces Pricing of Initial Public Offering
PR Newswire - Wed Apr 29, 5:56PM CDT
Blueprint Medicines today announced the pricing of its initial public offering of 8,145,834 shares of its common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. In addition, Blueprint Medicines granted the underwriters a 30-day option to purchase up to an additional 1,221,874 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on April 30, 2015 under the ticker symbol "BPMC."
BPMC: 28.26 (-0.17)
Blueprint Medicines - High Valuations On A Preclinical Pipeline
APBK Capital - at Seeking Alpha - Tue Apr 28, 10:05AM CDT
BPMC: 28.26 (-0.17)
Blueprint Medicines IPO: Early For Stamp Of Approval, But Goldman Could Power It Up
Don Dion - at Seeking Alpha - Tue Apr 28, 3:30AM CDT
BPMC: 28.26 (-0.17), ALXN: 197.94 (+0.79)
Week Ahead: 6 IPOs Planned For The Week Of April 27
Renaissance Capital IPO Research - at Seeking Alpha - Mon Apr 27, 5:53AM CDT
Up to six companies could price their IPOs this week . All are either LPs or healthcare companies (including three biotechs). Two LPs on deck, one offering power-generating wood pellets Enviva Partners LP (Pending: EVA ) is backed by...
BPMC: 28.26 (-0.17), EVA: 15.82 (-0.05), CLCD: 7.15 (-0.41), BSM: 13.89 (-0.54), VKTX: 6.10 (+0.20), OPGN: 3.22 (+0.07)
